The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 798
Rehabilitation for Physical Frailty in Lung Transplant Candidates: A Systematic Review
McGarrigle, L., Norman, G., Hurst, H., Gillespie, L., & Todd, C. J. (2024) · Cardiopulmonary Physical Therapy Journal · doi:10.1097/cpt.0000000000000265 · Cited by 4
Utility and bias in psychosocial evaluations for transplant listing
Ladin, K. (2025) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001198 · Cited by 5
Kim, G., Ahn, J. H., Shim, T. S., Kang, P. J., Lee, G. D., Choi, S., Kim, W. D., Jung, S., Kim, D. K., Park, S.-I., et al. (2025) · Transplant International · doi:10.3389/ti.2025.13944 · Cited by 5
Beyond the Graft: Recurrence of Interstitial Lung Diseases Post Transplant
Ntiamoah, P., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041093 · Cited by 4
“Re-transplants Re-transplants make up around 5% of all lung transplants [1,3,4].”
InfluentialNon-Pharmacological Management of Idiopathic Pulmonary Fibrosis
Mullholand, J. B., GROSSMAN, C. E., & Perelas, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041317 · Cited by 4
“It is thus not surprising that oxygen therapy is one of the key criteria for consideration for lung transplantation according to the latest guidelines [9].”
Pulmonary Hypertension and Lung Transplantation
Kruszona, S., Aburahma, K., de Manna, N. D., Bobylev, D., Ruhparwar, A., Kuehn, C., Salman, J., & Ius, F. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2590-2620 · Cited by 3
Facilitators and Barriers to Patient–Caregiver Dyadic Recruitment in Transplantation
Koons, B., Lehman, R., Riegel, B. J., & Buck, H. G. (2025) · Nursing Research · doi:10.1097/nnr.0000000000000838 · Cited by 3
Walsh, J., Morris, N. R., Yerkovich, S. T., Linnane, M. P., Chambers, D. C., & Hopkins, P. M.-A. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.05.018 · Cited by 3
Effect of Total Psoas Muscle Area and Serum Albumin on Outcomes After Lung Transplantation
Franco‐Palacios, D. J., Franco‐Palacios, C. R., Crowley, S., Allenspach, L. L., Stagner, L. D., Corrales, J. P., OLEXSEY, K. H., Waynick, L. K., Simanovski, J., Bhatti, H., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70308 · Cited by 2
“Guidelines recommend evaluating muscle quantity, quality, strength, and physical performance for sarcopenia diagnosis [7–9].”
InfluentialKarolak, W., Pastwa, K., Addo, S. A., Khan, S., Shinde, R., Nuur, I. M., Kumaravel, A., Reta, F. K., Wojarski, J., Maruszewski, M., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.049 · Cited by 3
Lung transplantation in patients with a history of anatomical native lung resection
İskender, İ., Pecoraro, Y., Moreno, P., et al. (2022) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivac256 · Cited by 3
Transplantation pulmonaire pour mucoviscidose et autres bronchectasies
Renaud-Picard, B., Tissot, A., Burgel, P., Grenet, D., de Miranda, S., & Coiffard, B. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.011 · Cited by 4
Taweesedt, P. T., Lertjitbanjong, P., Eksombatchai, D., Charoenpong, P., Moua, T., Thongprayoon, C., Tangpanithandee, S., & Petnak, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020655 · Cited by 4
“In the current clinical practice guideline from the ISHLT, antifibrotics may be continued in patients with ILD on the transplant waitlist until the time of LT [33].”
BackgroundCardiothoracic Transplant Anesthesia: Selected Highlights: Part I—Lung Transplantation
Courtwright, A., Devarajan, J., Fritz, A. V., Martin, A. K., Wilkey, B., Subramani, S., Cassara, C. M., Tawil, J. N., Miltiades, A., Boisen, M. L., et al. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.01.023 · Cited by 3
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, O., Pertseva, T. O., Ostrovsky, M. M., Basanets, A. V., Bychenko, O. V., Dziublyk, Y. O., Konopkina, L., et al. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-1-5-33 · Cited by 2
Pulmonary Function Prediction Equations—Clinical Ramifications of a Universal Standard
Gaffney, A. W. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.16129 · Cited by 3
Zhang, D., Wang, X., Du, W., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102243 · Cited by 3
Shiraishi, T., Midorikawa, K., Miyahara, S., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1861 · Cited by 3
“Lung transplant indications of individual candidates are basically screened according to the selection criteria of the International Society for Heart and Lung Transplantation (3).”
BackgroundBronchiectasis: literature review for preparation of 2024 clinical guidelines
Avdeev, S. N., Kondratyeva, E., Kozlov, R. S., Namazova-Baranova, L. S., Anaev, E. K., Mizernitsky, Y. L., Lyamin, A. V., Zyryanov, S. K., Gembitskaya, T. E., Tarabrin, E. А., et al. (2024) · PULMONOLOGIYA · doi:10.18093/0869-0189-2024-34-2-158-174 · Cited by 3
Sato, T., Tanaka, S., Sato, R., Kitao, K., Kai, S., Takeda, C., Ohsumi, A., Nakajima, D., Egawa, K., & Date, H. (2024) · Cureus · doi:10.7759/cureus.60029 · Cited by 5
“Regarding the indication for lung transplantation, the criteria proposed by the International Society for Heart and Lung Transplantation were referred to [15], and the indication was discussed by the Ethics Committee of Kyoto University Hospital and the review board in Japan.”
MethodCuesta, V. M. M., Meñaca, A. M., González-Fernández, Á., Fernandez, D. I., Tello-Mena, S., Izquierdo‐Cuervo, S., Fernández-Rozas, S., Alonso‐Lecue, P., & Martínez, J. M. C. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.04.022 · Cited by 3
Small recipient chest cavity from fibrotic lung disease in lung transplantation: Physiology matters
Eberlein, M. H., Reed, R. M., Gharaibeh, K. A., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100123 · Cited by 3
Li, S., Chen, S., Wang, Z., Zhao, C., Liu, H., & Jiao, W. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-430 · Cited by 3
Lv, J. (2024) · American Journal of Translational Research · doi:10.62347/ilkv4550 · Cited by 3
A Crossroads for Corticosteroid Therapy in Pediatric Interstitial and Rare Lung Diseases
Avdimiretz, N., Benden, C., Brugha, R. E., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202411-1138vp · Cited by 3
“The patient should also meet other criteria for referral for LTx according to the current International Society for Heart and Lung Transplantation guidelines (4); however, earlier consideration for referral can be considered in this scenario.”
Post-operative management of children after lung transplantation
Schwerk, N., Carlens, J., Köditz, H., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100301 · Cited by 3
“10 When listing patients for Ltx, it is essential to define individualized treatment plans that consider these factors.”
Self-citationFijołek, J., & Śniady, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134631 · Cited by 3
“Individualized risk assessment is essential because treatment outcomes vary [175].”
Assessment of listing criteria for lung transplant candidates with interstitial lung disease
Nagata, S., Ohsumi, A., Handa, T., Yamada, Y., Tanaka, S., Yutaka, Y., Nakajima, D., Tanizawa, K., Hirai, T., & Date, H. (2022) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-022-01861-z · Cited by 4
“Although the ISHLT criteria have been updated in 2021 [6], we used the 2014 criteria for the present study because most patients were registered based on the 2014 criteria.”
MethodInterstitial lung diseases: an overview
Karampitsakos, Τ., Wijsenbeek, M. S., Herazo‐Maya, J. D., Τzouvelekis, Α., & Kreuter, M. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10017322 · Cited by 3
Self-citationLung transplantation in Norway 1999–2020
Leuckfeld, I., Holm, A. M., Hoel, T. N., et al. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0775 · Cited by 3
Self-citationAnesthetic Management During Lung Transplantation – What’s New in 2021?
Brzeziński, M., Mladinov, D., & Neyrinck, A. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.001 · Cited by 3
Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List
Sayah, D. M., & Pilewski, J. M. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.002 · Cited by 3
Mularek‐Kubzdela, T., Wojnarski, J., Kamiński, K. A., Ochman, M., Kasprzak, J. D., Stącel, T., Kurzyna, M., Karolak, W., Mroczek, E., Kopeć, G., et al. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0259 · Cited by 3
Lung Transplantation in India: a Brief Review, Landmarks, Indian Scenario, and our Experience
Attawar, S., Manoly, I., & Shah, U. B. (2023) · Indian Journal of Surgery · doi:10.1007/s12262-023-03663-w · Cited by 3
“Disease-specific indications for lung transplantation are often more precise and should be abided to as per the ISHLT consensus statement [23, 24].”
BackgroundSelf-citationChronic Obstructive Pulmonary Disease
Geraci, T. C., & DeMaio, A. J. (2024) · Contemporary surgical clerkships · doi:10.1007/978-3-031-44645-0_19 · Cited by 3
Handgrip Strength in Lung Transplant Candidates and Recipients.
Polastri, M., Dell’Amore, A., Reed, R. M., & Pehlivan, E. (2023) · Experimental and Clinical Transplantation · doi:10.6002/ect.2023.0092 · Cited by 3
Chirurgie des alten Menschen – Thoraxchirurgie
Ehrsam, J. P., & Aigner, C. (2022) · Die Chirurgie · doi:10.1007/s00104-022-01772-y · Cited by 2
Lung Transplantation: Selection of Candidates
Thomas, C., Williams, M., & Shlobin, O. A. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2304197 · Cited by 2
Self-citationPascreau, T., Gougeon, M., Fessler, J., Chahabi, S. Z., Guen, M. L., & Vasse, M. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.11.029 · Cited by 3
Lobar Lung Transplantation: A Single-Center 10-Year Experience
Cruz, Z., Neri, F., Roxo, M., Figueiredo, C., Moita, C., Costa, A. R., Silva, J. S., Reis, J. E., Barbosa, J. M., Calvinho, P. A., et al. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.04.017 · Cited by 2
Mesnard, B., Glorion, M., Eddine, A. J., Roux, A., Branchereau, J., Neuzillet, Y., Sage, E., Lebrét, T., Hertig, A., Madec, F.-X., et al. (2024) · Annals of Transplantation · doi:10.12659/aot.944049 · Cited by 2
“For some it is a relative contraindication to lung transplantation [9] because it facilitates fluid overload and hence pulmonary edema.”
BackgroundManaging Silicosis in the United States
Kahn, M. R., Klinhom, C., Wallace, W. D., Edminster, S., Maher, T. M., & Huerta, L. E. (2024) · CHEST Pulmonary · doi:10.1016/j.chpulm.2024.100103 · Cited by 2
“36 We also routinely refer patients for transplant evaluation if they have PMF, pneumothorax at diagnosis, hemoptysis, or worsening imaging over 12 months (suggesting ongoing in fl ammation).”
Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients
Zhang, D., Du, W., Qin, W., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6146 · Cited by 2
Prognosis of incidental lung cancer in lung transplant candidates
Bouchez, C., Medraoui, C., Cazes, A., Khalil, A., Jébrak, G., Mal, H., Mordant, P., Castier, Y., Montravers, P., Debray, M., et al. (2024) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2024.101146 · Cited by 2
Cassir, N., Coiffard, B., Hadjadj, L., et al. (2024) · Transplantation Reports · doi:10.1016/j.tpr.2024.100170 · Cited by 2
Uyama, M., Handa, T., Uozumi, R., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-03075-8 · Cited by 2
“There is a consensus that lung transplantation should be considered for patients at high risk of death from lung disease within 2 years [32].”
An innovative prehabilitation approach for lung transplant candidates
Barr, K. P., Tankosich, G., & Willey, B. M. (2025) · PM&R · doi:10.1002/pmrj.13410 · Cited by 2
DELEIJA, J., Shah, S. Z., Felzer, J., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.05.021 · Cited by 2
Toyokawa, G., Yamaguchi, M., Yamaya, T., et al. (2025) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.25-00067 · Cited by 2
Relationships Between Nutrition Risk and Frailty in Candidates for Lung Transplant
Stewart, B., Brody, R. A., Samavat, H., Byham-Gray, L. D., Chowdhury, N., Mathur, S., & Singer, L. G. (2025) · Clinical Transplantation · doi:10.1111/ctr.70205 · Cited by 2
Ishaaya, E. C., Yee, N. K., & DeCato, T. W. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.04.006 · Cited by 3
Hardman, M., Higgi, S. A. H., Hanson, L., Schutz, K. C., Wargo, M. J., Tenebäck, C. C., Daniels, T. W. V., Gast, C., & Rivett, D. W. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00382-25 · Cited by 4
“…active disease, pwCF have shown a significant reduction in percentage predicted of forced expiratory volume in 1 second (%FEV 1 ) and increased frequency of exacerbations (10, 11) and may be ineligible for lung transplantation due to the intrinsic antimicrobial properties of some NTM species (12).”
Nauroz, Z., Ruck, J. M., Shah, P., Bush, E. L., Werbel, W. A., Raju, S., Hemmige, V. S., Haidar, G., Massie, A. B., Segev, D. L., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70090 · Cited by 4
“…such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary hypertension [4–8 , Given hypothetical concerns about the potential compounding effects of immunosuppression and HIV infection, LT was historically considered a contraindication for this population [10, 11].”
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
Tian, L., Wang, Y., Qi, W., Wang, B., Zhang, X., Gong, M., Zhang, X., & Wang, T. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.003 · Cited by 4
“For patients with IP, the International Society for Heart and Lung Transplantation suggested lung transplant consideration at diagnosis (Leard et al ., 2021).”
Kuhnert, S., Wilke, L., Sommerlad, J., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186420 · Cited by 2
“…Society of Heart and Lung Transplantation (ISHLT) has set criteria for referring ILD patients for LTx, including specific histopathologic or radiographic findings, abnormal lung function, dyspnea or functional limitations, oxygen requirement, and lack of improvement following medical therapy [10].”
InfluentialCurrent Perspectives on The Diagnosis and Management of Lymphangioleiomyomatosis
Saluja, P., & Gupta, N. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.07.002 · Cited by 2
Effect of Donor Age on Survival in Lung Transplantation: A Multicentric Retrospective Study
Reucherand, B., Tissot, A., Lacoste, P., Roux, A., Coiffard, B., Demant, X., Magnan, A., Renaud-Picard, B., Pavec, J. L., Merveilleux, C., et al. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf420 · Cited by 2
Engels, E. A., Castenson, D., Luo, Q., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.02.036 · Cited by 2
Lee, H., Cho, W. H., Kim, K., Kim, A. R., Oh, S.-H., Lee, J. G., Kim, S. Y., Park, S., Jeon, K., Hong, H., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.03.017 · Cited by 2
Chang, A., Saleh, N., Yu, A. C. M., Jalaledin, D. S., Hoa, S. A.-T., Levy, R. D., Wilson, J. M., Poirier, C. D., Choi, J., Yee, J., et al. (2026) · Rheumatology · doi:10.1093/rheumatology/keag200 · Cited by 2
“Suitability for lung transplantation was determined by the multidisciplinary transplant team after a comprehensive guideline-based assessment [14, 15].”
CHANG, S., Geraci, T. C., Stokes, J. W., Ahmad, U., Catarino, P., Ceulemans, L. J., Cypel, M., Halloran, K. M., Haney, J., Hartwig, M. G., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.03.620 · Cited by 4
Self-citationChallenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease
Tolle, L. B. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/9942432 · Cited by 3
“Lung transplantation should be evaluated for patients with IPF or with other ILDs that have not responded to treatment at an early stage [31].”
BackgroundHayes, D., Melicoff, E., & Ziady, A. G. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.02.015 · Cited by 2
Contre-indications à la transplantation pulmonaire
Hirschi, S., Pavec, J. L., Schuller, A., Bunel, V., Pison, C. M., & Mordant, P. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.006 · Cited by 2
Social Support: From Exclusion Criteria to Medical Service
Appel, J. M. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000014 · Cited by 2
Farrell, J., & Ho, L. A. (2023) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s399518 · Cited by 2
“Lung transplant is a therapeutic option for a select minority of patients with SSc-ILD who progress despite therapy and do not have contraindications.(59) Post-transplant mortality in patients with SSc-ILD is similar to that in patients with other forms of ILD.”
BackgroundCuesta, V. M. M., Tello-Mena, S., Izquierdo‐Cuervo, S., Fernandez, D. I., Sánchez-Moreno, L., Ballesteros, M. Á., Alonso‐Lecue, P., Portal, F. O., Pargada, D. J. F., Miñambres-García, E., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004698 · Cited by 2
Pai, V. B., Asgari, E., Berman, M., et al. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100794 · Cited by 2
Outcomes of lung transplantation for chronic obstructive pulmonary disease
Türkkan, S., Başaran, F. Ç., Şahin, M. F., Beyoğlu, M. A., Bindal, M., Yazıcıoğlu, A., & Yekeler, E. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239703 · Cited by 2
“Moy The BODE score is recommended by ISHLT as a predictor for COPD recipient candidate selection (11).”
BackgroundMethodKoc, Ö. M., Aslan, D., Kramer, M., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.15171 · Cited by 2
“21 The COPD patients in our series had only moderate airflow limitation severity based on FEV 1 between 50% and 80%, and accordingly no indication for lung transplantation.”
BackgroundOutcomes associated with prolonged ECMO in COVID-19 associated ARDS: A single center experience
Shah, P., Miller, C. F., Parilla, G., et al. (2023) · Perfusion · doi:10.1177/02676591231184710 · Cited by 2
Women After Solid Organ Transplantation: An Overview of Gynecological Health
Juliato, C. R. T., Guida, J. P. D. S., & Surita, F. G. (2023) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v26i1.544_eng · Cited by 2
Lungentransplantation: aktueller Stand und Entwicklungen
Michel, S. G., Hagl, C. M., Kauke, T., et al. (2024) · Die Chirurgie · doi:10.1007/s00104-023-02023-4 · Cited by 2
Mieszczański, P., Janiak, M., Ziemiański, P., Cylke, R., Lisik, W., & Trzebicki, J. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.942736 · Cited by 2
“However, one of the factors that can significantly restrict eligibility and increase the risk of such management is obesity with a body mass index (BMI) of 35 or more [5], which can be associated with post-transplant increase in mortality and primary graft dysfunction [6].”
BackgroundEvaluation of Candidates for Lung Transplant—A Review of Patient-Specific Risk Factors
Leard, L. E. (2024) · Current Pulmonology Reports · doi:10.1007/s13665-024-00339-y · Cited by 3
Self-citationLung Transplantation in Pulmonary Arterial Hypertension: The Portuguese Experience
Matias, M. V., Cruz, Z., Figueiredo, C., Moita, C., Roxo, M., Reis, J. E., Costa, A. R., Silva, J. S., Barbosa, J. M., Calvinho, P. A., et al. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.01.013 · Cited by 2
Cuesta, V. M. M., Meñaca, A. M., Fernandez, D. I., Tello-Mena, S., Izquierdo‐Cuervo, S., Camarero, T. G., Ongay, A. G., Sánchez-Moreno, L., Alonso‐Lecue, P., Naranjo-Gozalo, S., et al. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.12.019 · Cited by 2
Imaging of Lung Transplantation
Kim, S. J., Short, R. G., Beal, M. A., et al. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.02.014 · Cited by 2
A single-centre analysis of lung transplantation outcomes in recipients aged 70 or older
Kashem, M. A., Calvelli, H. R., Warnick, M., Kehara, H., Dulam, V., Zhao, H., Yanigada, R., Shigemura, N., & Toyoda, Y. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae150 · Cited by 2
Weight loss with GLP-1 analogues in preparation for transplantation
O’Callaghan, M., le Roux, C. W., Fabre, A., & McCarthy, C. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-256099 · Cited by 2
Khan, S. L., Danoff, S. K., Kulkarni, T., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202402-141rl · Cited by 2
Self-citationPatient selection, surgery and perioperative management in lung transplantation in Japan
Konoeda, C., & Sato, M. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-374 · Cited by 2
Should Antimicrobial Resistance Limit Access to an Organ Transplant?
Courtwright, A. (2024) · The AMA Journal of Ethic · doi:10.1001/amajethics.2024.367 · Cited by 2
Sakurai, T., Kanou, T., Funaki, S., Fukui, E., Kimura, T., Ose, N., Inoue, Y., & Shintani, Y. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.05.008 · Cited by 2
Differential effects of donor factors on post-transplant survival in lung transplantation
Lehr, C. J., Dalton, J. E., Dewey, E. N., Gunsalus, P. R., Rose, J., & Valapour, M. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100122 · Cited by 2
“36 Another challenge in studying individual factors is the risk for a Table 2 fallacy where multiple adjusted effect estimates are presented from a single model which can lead to inaccurate interpretations of the effect estimates for confounders.”
Self-citationHoang, T.-C.-T., Han, L., Hirschi, S., Dégot, T., Leroux, J., Falcoz, P., Olland, A., Santelmo, N., Villard, M., Collange, O., et al. (2024) · Annals of Transplantation · doi:10.12659/aot.944420 · Cited by 3
“…(LTx) has been established as an effective and life-extending therapy for specific patients with terminal lung diseases, such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, alpha-1 antitrypsin deficiency, cystic fibrosis, and pulmonary arterial hypertension [1].”
BackgroundAntibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study
Pascale, R., Tazza, B., Amicucci, A., Salvaterra, E., DOLCI, G. G., Antonacci, F., Baiocchi, M., Pastore, S., Ambretti, S., Peghin, M., et al. (2024) · Transplant International · doi:10.3389/ti.2024.13245 · Cited by 4
“The most frequent lung diseases requiring transplantation, COPD/emphysema and cystic fi brosis, are poor represented in our study [21].”
BackgroundKim, H. C., Fonseca, O. C., Tehrani, B. N., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100160 · Cited by 2
Self-citationRecipient selection for lung transplantation: perspective in decision-making
Sarıbaş, E., & Çitak, S. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae144 · Cited by 2
Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-Up
Odish, M. F., Pollema, T. L., Lin, C. M., Owens, R. L., Yi, C., Leblanc, S. K. D., Roche, C. E., Gaissert, C., Yung, G., Kafi, A., et al. (2024) · Annals of Transplantation · doi:10.12659/aot.946088 · Cited by 2
El‐Kersh, K., Bag, R., Bhatt, N., King, C. S., Waxman, A. B., Rischard, F. P., Kim, H., Cella, D., Shen, E., & Nathan, S. D. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100206 · Cited by 3
Atchade, E., Bunel, V., Zappella, N., Jean‐Baptiste, S., Tran‐Dinh, A., Tanaka, S., Lortat‐Jacob, B., Roussel, A., Mordant, P., Castier, Y., et al. (2025) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2025.101499 · Cited by 2
Krejčí, Š., Stavrakakis, H.-A., Barták, M., et al. (2025) · Czech Polar Reports · doi:10.5817/cpr2024-2-20 · Cited by 2
Caregiver burden in lung transplantation: A review
Sankar, K., Johnson, A., McRae, K., Rampolla, R. E., & Kolaitis, N. A. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100239 · Cited by 4
Self-citationPérez, A. I., Ibáñez, S. A., Castillo, S. S., Lacaba, G. P., Rubio, E. R., Hernández, R. L., Chinarro, B. J., & Almonacid, C. (2025) · Open Respiratory Archives · doi:10.1016/j.opresp.2025.100432 · Cited by 2
Genecand, L., Wacker, J., Guerreiro, I., Lechartier, B., Beghetti, M., Pohle, S., Darie, A. M., Lichtblau, M., Ulrich, S., Guler, S. A., et al. (2025) · Respiration · doi:10.1159/000544800 · Cited by 2
“Therefore, PH is included in the criteria for lung transplantation listing in ILDs [17].”
Active smokers should not be denied access to lung transplantation
Courtwright, A. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.04.022 · Cited by 2
Balasubramanian, P., Franco, P. M., Chaudhary, S., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100287 · Cited by 2
“4-6 Among the ESLD, interstitial lung disease (ILD) is the most common etiology bridged with ECMO for LTx. 7 Prevalence of pulmonary hypertension associated with ILD (PH-ILD) is thought to increase with progressive ILD and during acute exacerbations due to a combination of chronic hypoxia, endothelial dysfunction, and…”
InfluentialThe prognostic value of the TAPSE/PASP ratio in lung transplant candidates
Bıyıklı, K., Keskin, B., Karagöz, A., et al. (2025) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2025.26847 · Cited by 2
Lung transplantation for chronic thromboembolic pulmonary hypertension—a case series
Darie, A. M., Doi, A., Levvey, B. J., Shingles, H. V., Yo, S. W., Williams, T., & Snell, G. I. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.09.026 · Cited by 2
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
